AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$HRMY

Harmony Biosciences Holdings earnings missed by $0.30, revenue fell short of estimates

Harmony Biosciences (HRMY) reported Q3 EPS of $0.81, missing estimates by $0.30, and revenue of $268.91M, below expectations. The company forecasts FY 2026 revenue of $1.00B-$1.04B, slightly below consensus. HRMY stock is down 3.62% over 3 months but up 18.09% year-over-year, with a Financial Health score rated 'excellent'.

Original reporting
investing.com
Published Nov 4, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HRMY
Bearish
high confidence
Mentioned
$HRMY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HRMYBearishMed
01

Why it matters

The miss may trigger short-term selling pressure but longer-term outlook depends on pipeline progress.

02

Market read

Earnings miss is a primary catalyst for HRMY; limited broader market effect.

03

What to watch

Potential pipeline milestones or upcoming data releases not mentioned could offset the miss.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Harmony Biosciences reported Q3 results that fell short of analyst expectations and provided slightly lower FY revenue guidance.

Company-level read

Ticker impact

$HRMYBearishHigh confidence
Context

Q3 earnings missed EPS and revenue estimates; guidance lowered versus consensus.

Expected impact

downward pressure as investors price in the miss and lower outlook

Evidence & confidence

Both EPS and revenue fell short of expectations and FY guidance was trimmed, a clear negative catalyst.

Market effects

Sector

Biotech earnings miss may weigh on peer valuations briefly.

Regional

Limited to US-listed biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

If the miss is already priced in, the stock could rebound on short-covering.

Key entities

  • company
    Harmony Biosciences Holdings

    Biotech firm listed on NASDAQ (HRMY).

Read at source← All news

Related articles

NOV 4
$HRMYMed

Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary

Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.

tradingview.com1 min
NOV 4
$HRMYMedAI 8/10

Harmony Biosciences Reports Q3 Financial Results

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $2

SEC EDGAR 8-K2 min